Search
Now showing items 1-10 of 15
Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/ hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects
(2020-06)
Mental disorders frequently begin in childhood or adolescence. Psychotropic medications have various indications for the treatment of mental disorders in this age group and are used not infrequently off‐label. However, ...
Initial treatment choices to achieve sustained response in major depression: a systematic review and network meta-analysis
(2021-10)
Major depression is often a relapsing disorder. It is therefore important to start its treatment with therapies that maximize the chance of not
only getting the patients well but also keeping them well. We examined the ...
Substance use disorder treatment success: assessing patient-reported use improvement and provider-evaluated treatment completion
(2021-11)
Provider-evaluated substance use treatment completion and client-reported substance use improvement are standards in determining treatment success. The relationship between these two outcomes is anecdotally understood in ...
Knowledge and Use of Novel Psychoactive Substances in Italy: a Survey-Based Study in the General Population
(2021-11)
In this study, we aimed to identify the current trend of novel psychoactive substance (NPS) consumption in Italy and the level of knowledge about NPS in the general population and to explore the presence of risk factors ...
COVID-19 and substance use disorders: a review of international guidelines for frontline healthcare workers of addiction services
(2022-03)
People with substance use disorders may be at a greater risk of contracting COVID-19 infection and developing medical complications. Several institutional and governmental health agencies across the world developed ad hoc ...
Efficacy of tiapride in the treatment of psychiatric disorders: A systematic review
(2022-03)
Tiapride is an atypical antipsychotic used to treat alcohol withdrawal, aggressiveness and agitation, headache, dyskinesias, tic and Tourette's disorder. More recently, it has been proposed for the treatment of delirium ...
Development and validation of a meta-learner for combining statistical and machine learning prediction models in individuals with depression
(2022-05)
The debate of whether machine learning models offer advantages over standard statistical methods when making predictions is ongoing. We discuss the use of a meta-learner model combining both approaches as an alternative. ...
Covid-19 and mental health: a transformational opportunity to apply an evidence-based approach to clinical practice and research
(2020-04)
The Oxford Precision Psychiatry Lab (https://oxfordhealthbrc.nihr.ac.uk/our-work/oxppl/, @OxfordPPL) collected from senior clinicians in the local Mental Health Trust a list of specific and focused questions about mental ...
Optimal dose of brexpiprazole for augmentation therapy of antidepressant-refractory depression: A systematic review and dose-effect meta-analysis
(2022-06)
Background: Brexpiprazole augmentation is an effective treatment strategy for antidepressant-refractory depression, but its optimal dosage remains unclear.
Aims: To find the optimal dosage of brexpiprazole as augmentation ...
Off–label long acting injectable antipsychotics in real–world clinical practice: a cross-sectional analysis of prescriptive patterns from the STAR Network DEPOT study
(2022-06)
Introduction
Information on the off–label use of Long–Acting Injectable (LAI) antipsychotics in the real world is lacking. In this study, we aimed to identify the sociodemographic and clinical features of patients treated ...